Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

Research and Innovation Action · Running

IMMEDIATE Imminent Disease Prediction and Prevention at the Environment Host Interface

Coordinator
Charite - Universitaetsmedizin Berlin, Germany
Runs
1 January 2023 to 31 December 2026
Status
Running
EU funding
€6.2m
Total cost
€6.2m
Partners
13 organisations in 7 countries
Type
Research and Innovation Action
Grant agreement
101095540

What the project is doing

In the project's own words, from its summary on CORDIS.

IMMEDIATE aims to investigate and explore the diet-microbiome-immunometabolism-axis as a sensor for health-to-disease transition and evaluate strategies to maintain an individual’s well-being. Chronic inflammation is the major root of most diseases. Understanding of this process preceding organ dysfunction or damage and identification of biomarkers in the pre-symptomatic stage and risk but also resilience factors of health-to-disease transition will enable targeted and personalized interventions to prevent irreversible organ damage.

Metabolites of gut microbiota are key messengers between diet, microbiota and host, maintaining the balance of pro- and anti-inflammation. Our study takes advantage of cutting-edge omics technologies available within the IMMEDIATE consortium in conjunction with available clinical data and biospecimens from ongoing observational studies, enrolling “healthy” subjects and individuals in the pre-disease stage but with largely distinct environmental and dietary modulators, including a cohort of kidney transplant recipients in whom renal function has been “reset to baseline”.

The identification of clinical and omics-derived biomarkers will – by employing AI algorithms - yield a personalized risk / resilience score of chronic inflammation and thus a better prediction of an individual’s risk of transition towards disease. A proof-of-concept intervention study with the anti-inflammatory microbe Akkermansia muciniphila will be conducted to test whether deflections of the microbiome-metabolite-immune axis can be reverted on the biomarker level but also with respect to clinical outcomes and overall well-being.

Mobile apps developed by the IMMEDIATE consortium in collaboration with patient organizations tracking numerous lifestyle-related measures and providing guidance and feedback on these aspects will empower individuals to adopt and integrate these knowledge-based health interventions into their own lives, hereby self-managing their own health.

Who is involved

OrganisationCityCountryRole
Charite - Universitaetsmedizin BerlinBerlinGermanyCoordinator
The Akkermansia CompanyOttignies-Louvain-la-NeuveBelgiumParticipant
Bundesverband Niere E.v.MainzGermanyParticipant
Eurice European Research and Project Office GmbHSt IngbertGermanyParticipant
Max Delbrueck Centrum Fuer Molekulare Medizin in Der Helmholtz-Gemeinschaft (mdc)BerlinGermanyParticipant
Universitaetsklinikum EssenEssenGermanyParticipant
Universitatsklinikum ErlangenErlangenGermanyParticipant
Research and Innovation Services Doo Za UslugeZagrebCroatiaThird party
Weizmann Institute of ScienceRehovotIsraelParticipant
Zadig SRLMilanoItalyParticipant
Pomorski Uniwersytet Medyczny W SzczecinieSzczecinPolandParticipant
Sanprobi Spolka Z Ograniczona Odpowiedzialnoscia Spolka KomandytowaSzczecinPolandParticipant
Imperial College of Science Technology and MedicineLondonUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI